### Customer No. 28880

### IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT : Gerwyn Bish, et al. EXAMINER :

SERIAL NO. : ART UNIT :

FILED : CONF. NO. :

FOR : PIPERAZINE DERIVATIVES WHICH EXHIBIT ACTIVITY AS

SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS

# Statement as Provided by 37 CFR 1.97(b)

Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

### Dear Sir:

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

It is requested that the references listed on the attached form PTO-SB-08A/08B be included in the "References Cited" portion of any patent issuing from this application (MPEP § 1302.12).

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully submitted,

Paul M. Misiak

Registration No. 58,310

Warner-Lambert Company LLC 2800 Plymouth Road

Ann Arbor, MI 48105 Telephone: (734) 622-1435 Facsimile: (734) 622-2928

Dated: July 13, 2006

## SAP20 Rec'd PCT/PTO 13 JUL 2006 Confirmation No.

PTO/SB/08A (07-05) Approved for use through 07/31/2006. OMB 0651-0031

	Under t	ne Paperwork Reduction	n Act of 1	95, no persons are required to		mark Office; U.S. DEPARTMENT OF COMMERCI Lion unless it contains a valid OMB control number
	Subst	tute for form 1449/PTC	,		Co	mplete if Known
					Application Number	10/580029
	INII	CODMATIO	N DI	SCLOSURE	Filing Date	
					First Named Inventor	Gerwyn Bish, et al.
	SI			PPLICANT	Art Unit	
		(Use as many s	heets as	necessary)	Examiner Name	
$\overline{}$	Sheet	1	of	2	Attorney Docket Number	PC32050A

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (F Innom)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		<sup>US-</sup> 4,162,316	07-24-1979	Nakamura, Hideo et al.	
		<sup>US-</sup> 5,561,152	10-01-1996	Freedman et al.	
		US-			
		US-			
		US-			
	_	US-			
		US-	-		
		US-			
		US-			
		us-	-		
		US-			

Exeminer Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Petentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Pessages Or Relevant Figures Appear	7°
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
						F
				-		ł
						t
						I
						Ľ
Examiner Signature	Т-	/Erich Leeser/		Date Considered	01/30/2008	-

FEARMINET intelligence which are on the classifier of the considered include copy of the form with enterpretable considered include copy of the form with next communication to applicant. Applicant's various classon designation manufact (optional). See Kinds Order See Ki

Transition is attached.
Transition is a formation is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFT) to proceed an application. Confidentially is governed by 38 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including attending, repeating, and subtraining the completed application from the USFTD. Times will vary depending upon the antividual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheel Information Officer, U.S. Palant and Trademark Office, P.O. Box 1560, Alexandria, V.A. 223-1546. D. ON OT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS TO THIS ADDRESS TO SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH, /EL/

Approved for use through 07/31/2006. OMB 0651-0031 and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	e for form 1449/PTO	uction Ac	t of 1995, no persons ar	required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known			
Gassiiai				Application Number	10/586029		
			CLOSURE	Filing Date	*9,30005		
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	Gerwyn Bish, et al.		
	(Usa as many she	ete ac e		Art Unit			
	losa as many sne	ecs as m	cessary)	Examiner Name			
Sheet	2	of	2	Attorney Docket Number	PC32050A		

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		KAGAYAKI NATSUKA ET AL, "Synthesis and Structure-Activity Relationship of 1-Substituted 4-(1,2-Diphenylethyl)Fiperazine Derivatives having Parcotic Ageomists and Antagonist Activity", Journal of Medicinal Chemistry, Am. Chem Soc., (1987), pp 1779-1787, Vol. 30	
		BOLL1, M.H. ET AL, "Development of a polymer bound Wittig reation and use in multi-step organic synthesis for the overall conversion of alcohols to beta-hydroxyamines". J. Chem Soc., (1998), pp. 2243-2246	
		SHIMOKAWA, N. ET AL., "Studies on analgesic agents. 1. Preparation of 1,2diphenyl-2-(4-substitued-1-piperaziny 1)cthanol derivatives and structure-activity relationship", J. Med. Chem, (1979), pp 58-63, Vol. 22	
		NATSUKA. K. ET AL, "Studies on 1-Substituted 4-(1,2-Diphenylethyl)Piperazine Derivatives and their Analgesic Activities", J. Med. Chem., (1975), pp 1240-1244, Vol. 18	
		Database Crossfire Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt-Main, De; Database accession no. BRN: 561221, Abstract	
		ARTIGAS, F., "Selective Serotonin/Noradrenaline reuptake Inhibitors (SNRIS) Pharmacology and Therapeutic Potential in the Treatment of Depressive Disorders", CNS Drugs, (1995), pp 70-89, Vol. 4	

Examiner		Date	01/30/2008
Signature	/Erich Leeser/	Considered	01/30/2000

<sup>&</sup>quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

consistency include copy of the size when the contributation is displaced in the contributation of the contrib